Yes, Cassava management is being a bit disingenuous with this. The issues are with a recent lab report and clinical trial presentation, not a 2012 research paper. I think it's going to sink that this is not 'vindication'. The issues weren't addressed unfortunately.
Folks need too read carefully and objectively to be good investors.
Market Data 
Markets 
AI
